Dr. Pol Boudes to leave CymaBay Therapeutics — 4 insights

Clinical-stage biopharmaceutical company CymaBay Therapeutics will lose its CMO Pol Boudes, MD, who is leaving the company on his own accord.

What you should know:

1. Dr. Boudes will resign Sept. 30.

2. CymaBay began searching for his replacement.

3. Gideon Hirschfield, MD, will provide medical and clinical support while the company searches for a fulltime replacement.

4. CymaBay is developing treatments for liver and other chronic diseases.

More articles on surgery center:
ASC supply chain tip of the day: Rely on data
Prevent cross contamination with single sterile IV start kits
Medline to Expand Southeast Distribution with New North Carolina Center

© Copyright ASC COMMUNICATIONS 2021. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.